The incidence rate of TB in patients with cancer exposed to ICIs
| ICI exposure | ICI non-exposure | |||||||
| n (%) | TB events | Person-years | Incidence* (95% CI) | n (%) | TB events | Person-years | Incidence* (95% CI) | |
| Total | 5037 (100.0) | 20 | 2959 | 675.8 (412.8 to 1043.8) | 136 513 (100.0) | 896 | 149 562 | 599.1 (560.5 to 639.6) |
| Sex | ||||||||
| Male | 3752 (74.5) | 16 | 2173 | 736.5 (421.0 to 1196.0) | 92 050 (67.4) | 676 | 98 733 | 684.7 (634.0 to 738.3) |
| Female | 1285 (25.5) | 4 | 787 | 508.3 (138.5 to 1301.6) | 44 463 (32.6) | 220 | 50 829 | 432.8 (377.5 to 494.0) |
| Age (years) | ||||||||
| 20–29 | 8 (0.2) | 0 | 5 | 288 (0.2) | 3 | 319 | 939.7 (193.8 to 2746.1) | |
| 30–39 | 40 (0.8) | 0 | 26 | 1278 (0.9) | 6 | 1464 | 409.9 (150.4 to 892.2) | |
| 40–49 | 269 (5.3) | 1 | 184 | 544.4 (13.8 to 3033.0) | 5805 (4.3) | 28 | 6992 | 400.5 (266.1 to 578.8) |
| 50–59 | 976 (19.4) | 4 | 607 | 658.7 (179.5 to 1686.6) | 20 749 (15.2) | 86 | 25 013 | 343.8 (275.0 to 424.6) |
| 60–69 | 1793 (35.6) | 6 | 1058 | 567.3 (208.2 to 1234.7) | 40 364 (29.6) | 258 | 47 363 | 544.7 (480.3 to 615.4) |
| 70–79 | 1615 (32.1) | 5 | 914 | 546.8 (177.5 to 1276.0) | 46 003 (33.7) | 335 | 49 406 | 678.1 (607.4 to 754.7) |
| ≥80 | 336 (6.7) | 4 | 165 | 2422.3 (660.0 to 6202.1) | 22 026 (16.1) | 180 | 19 006 | 947.1 (813.8 to 1096.1) |
| Type of cancer | ||||||||
| NSCLC | 3988 (79.2) | 19 | 2336 | 813.2 (489.6 to 1269.9) | 94 208 (69.0) | 752 | 96 624 | 778.3 (723.6 to 836.0) |
| Urothelial carcinoma | 337 (6.7) | 0 | 173 | 38 931 (28.5) | 135 | 49 047 | 275.3 (230.8 to 325.8) | |
| Melanoma | 712 (14.1) | 1 | 450 | 222.0 (5.6 to 1237.0) | 3374 (2.5) | 9 | 3891 | 231.3 (105.8 to 439.0) |
*Indicates incidence rate per 100,000 person-years.
ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; TB, tuberculosis.